Takeda Pharmaceutical Company Limited provided consolidated earnings guidance for the fiscal year ending March 31, 2023. The company expects revenue to be JPY 3,690,000 million, Operating profit to be JPY 520,000 million, net profit attributable to owners of parent to be JPY 292,000 million or JPY 188.13 per basic share.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4,049 JPY | -0.98% | -2.34% | -0.12% |
Apr. 18 | Takeda Says FDA Has Approved Subcutaneous Entyvio for Crohn's Disease | DJ |
Apr. 16 | Takeda Pharmaceutical to Issue 2nd Hybrid Bonds in Mid-2024 to Refinance 500 Billion Yen 1st Hybrid Bonds | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.12% | 41.16B | |
+27.97% | 676B | |
+23.58% | 554B | |
-7.02% | 349B | |
+14.85% | 318B | |
+6.25% | 291B | |
+2.96% | 210B | |
-0.41% | 204B | |
-10.02% | 194B | |
-11.81% | 144B |
- Stock Market
- Equities
- 4502 Stock
- News Takeda Pharmaceutical Company Limited
- Takeda Pharmaceutical Company Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023